secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2022-09-07T23:59:59+00:00
Accession:  0001493152-22-025265
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace sells Pharma Services unit to Flagship for $7M; expects ~$5M annual cash flow improvement
--------------------------------------------------------------------------------

- Sold Pharma Solutions business to Flagship Biosciences for ~$7M cash at close (plus up to $2M earnout based on revenue).
- Transaction improves operating cash flow by nearly $5M annually, per CEO.
- Pro forma: six-month 2022 operating loss narrows from $5.8M to $2.9M after sale.
- Company becomes focused molecular diagnostics firm (PancraGEN, ThyGeNEXT, ThyraMIR, RespriDX, BarreGEN).
- Ampersand and BroadOak affiliates provided equity to Flagship; Ampersand holds ~4.7M shares of Interpace common via Series B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222025265/0001493152-22-025265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315222025265/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-025265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer